Drug intelligence / Profile preview

euphrasia + cyclosporin

Development stage
Unknown
Lead developer
University of Missouri
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Euphrasia + cyclosporin is an experimental combination therapy investigated by the University of Missouri-Columbia for the treatment of moderate to severe dry eye syndrome (keratoconjunctivitis sicca). This regimen combines a homeopathic ophthalmic solution derived from the plant *Euphrasia officinalis* (commonly known as Eyebright) with cyclosporin, a well-established immunosuppressant. Cyclosporin acts as a calcineurin inhibitor, blocking the activation of T-lymphocytes and the subsequent production of pro-inflammatory cytokines such as interleukin-2 (IL-2). By reducing chronic inflammation of the ocular surface and lacrimal glands, cyclosporin helps restore natural tear production. Euphrasia is traditionally used in homeopathic medicine for its astringent and anti-inflammatory properties to relieve eye irritation. The combination is studied to determine if the addition of homeopathic Euphrasia provides synergistic clinical benefits over cyclosporin monotherapy in improving tear film stability and patient comfort.

Other names
Euphrasia-based homeopathic therapy + cyclosporinEuphrasia + RestasisEuphrasia + cyclosporine
02

Targets

CN (Calcineurin)

Beyond the preview

Go deeper on euphrasia + cyclosporin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on euphrasia + cyclosporin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call